Overview

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Status:
Completed

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with bortezomib and bortezomib alone in subjects with relapsed or refractory multiple myeloma (MM).

Phase:

Phase 2

Details

Lead Sponsor:

Human Genome Sciences Inc.

Treatments:

Antibodies, Monoclonal
Bortezomib
Mapatumumab